Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May;35(4):981-986.
doi: 10.1007/s12640-019-00015-z. Epub 2019 Feb 23.

The Neuroprotective Effect of Doxycycline on Neurodegenerative Diseases

Affiliations
Review

The Neuroprotective Effect of Doxycycline on Neurodegenerative Diseases

Flávia Viana Santa-Cecília et al. Neurotox Res. 2019 May.

Abstract

Neurodegenerative diseases (NDs) are a group of chronic, progressive disorders characterized by the gradual loss of neurons that affect specific regions of the brain, which leads to deficits in specific functions (e.g., memory, movement, cognition). The mechanism that drives chronic progression of NDs remains elusive. Among the proposed underlying pathophysiological mechanisms, aggregation and accumulation of misfolded proteins and neuroinflammation have been credited to contribute to extensive neural loss. Therapeutic agents that confer neuroprotection by downregulating these shared characteristics could therefore have beneficial effects on a wide range of NDs. In this regard, a commonly used antibiotic, doxycycline (Doxy), has been shown to reduce the progression and severity of disease in different experimental models of neurodegeneration by counteracting these common features. This review will focus on the effects reported for Doxy regarding its neuroprotective properties, the "off-target" effects, thereby supporting its evaluation as a new therapeutic approach for diseases associated with a neurodegeneration.

Keywords: Doxycycline; Less neurons; Misfolded proteins; Neurodegeneration; Neuroinflammation.

PubMed Disclaimer

Similar articles

Cited by

References

    1. FEBS Lett. 2001 Jan 5;487(3):404-7 - PubMed
    1. N Engl J Med. 2001 May 17;344(20):1516-26 - PubMed
    1. Brain. 2001 Nov;124(Pt 11):2203-14 - PubMed
    1. Science. 2003 Apr 18;300(5618):486-9 - PubMed
    1. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Aug;27(5):741-9 - PubMed

MeSH terms

LinkOut - more resources